Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants.

Autor:	Mausteller, Kyle G, Eisele, Caroline D, Julian, Katherine, Patel, Puja, Bansal, Amit, Jain, Rahul, Jain, Rohit
Předmět:	OBESITY complications PYRIDINE STROKE BODY weight ORAL drug administration ATRIAL fibrillation ANTICOAGULANTS BODY mass index HEMORRHAGE VITAMIN K DISEASE complications
Zdroj:	Future Cardiology; Nov2022, Vol. 18 Issue 10, p829-837, 9p
Abstrakt:	Obesity is an epidemic with rising prevalence, and obese patients are predisposed to comorbid conditions that increase risk for thromboembolic events. It is critical to identify safe and effective anticoagulation therapy for use in this population. Direct oral anticoagulants (DOACs) are a preferred option for anticoagulation in patients of normal weight due to many benefits and equivalent safety and efficacy to their vitamin K antagonist counterparts. However, the safety and efficacy of DOACs in obese patients is not well understood. This review describes recent studies on the pharmacokinetics, safety and efficacy, and clinical outcomes of the DOACs apixaban, rivaroxaban, edoxaban and dabigatran in obese patient populations. DOACs may be a beneficial alternative to vitamin K antagonist therapy in obese patient populations. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu